### **Company Overview** Aarti Pharmalabs Limited (APL) is a globally recognized Indian manufacturer and a leading small-molecule Contract Development and Manufacturing Organization (CDMO/CMO). Established in 1984 as a subsidiary of Aarti Industries Limited, APL became a separately listed entity following the demerger effective July 2021 (completed in October 2022). The company is part of the diversified Aarti Group, which has a group turnover exceeding ₹130 billion (FY25). APL specializes in the development and manufacturing of **high-value Active Pharmaceutical Ingredients (APIs)**, **Advanced Intermediates**, and **Xanthine Derivatives**, with a strong focus on regulated markets including the U.S., EU, Japan, Korea, and Mexico. It operates across three core business segments: 1. **APIs & Intermediates** (44% of revenue) 2. **Xanthine Derivatives & Allied** (43% of revenue) 3. **CDMO/CMO Services** (13% of revenue) APL serves over **500 global B2B customers** across 50+ countries, including big pharma, innovators, biotech firms, and leading beverage manufacturers. --- ### **Core Competencies and Offerings** #### **1. Specialized Manufacturing Expertise** - **Highly Potent APIs (HPAPIs)**: Specializes in oncology, corticosteroids, and cytotoxic medicines, with dedicated and compliant manufacturing facilities. - **Complex Chemistries**: Expertise in cyanation, flow chemistry, biocatalysis, nucleotide synthesis, cryogenic reactions (down to –80°C), hydrogenation, and high-temperature/vacuum distillation. - **Backward Integration**: Fully backward-integrated for most APIs and key intermediates, minimizing reliance on Chinese raw materials—positioning APL as a key beneficiary of the **"China+1" supply chain shift**. #### **2. Regulatory Compliance & Global Reach** - Facilities are approved by **USFDA, EU GMP, EDQM, KFDA (Korea), COFEPRIS (Mexico)**, and other global regulators. - Holds **50 US Drug Master Files (USDMFs)** and **31 European Certificates of Suitability (CEPs)**, enabling access to high-value regulated markets. - Strategically located manufacturing units in **western India** (Maharashtra and Gujarat), ensuring proximity to major ports for efficient export logistics. #### **3. Therapeutic Portfolio & Product Diversity** - Offers **55 commercialized APIs** across diverse therapeutic areas: - Oncology, Anti-diabetic, Cardiovascular, CNS, Anti-asthmatic, Dermatology, Anti-thalassaemic, Analgesics, Overactive Bladder, and Decongestants. - Serves pharma, nutraceutical, and cosmetic industries. - Supplies **140+ generic intermediates** and **125+ advanced intermediates** at R&D, pilot, and commercial scales. #### **4. Xanthine Derivatives – Market Leadership** - **Largest Indian manufacturer** of Xanthine derivatives, including **caffeine, theophylline, aminophylline, and etophylline**. - Applications: Pharmaceuticals (asthma, COPD), beverages (energy drinks, colas), nutraceuticals, and cosmetics. - **Global market share: 15–20%**, with a strategic goal to reach **20–25%** and become a **top-three global producer**. - Capacity: Expanding from **5,000 to 9,000 metric tons per annum (MTPA)** via a brownfield project in Tarapur, Maharashtra (Capex: ₹150 crores). - ~54% of demand comes from beverage customers (e.g., major cola brands – supplied under strict confidentiality). - Certifications: **Star Kosher, HACCP, Sedex SMETA-4Pillar, FSSC22000 (GFSI), and GMP**. - Currently produces ~500 MT/month, with **80–90% projected capacity utilization** post-expansion (by Q1 FY27). --- ### **CDMO/CMO – Strategic Growth Engine** APL is a **leading small-molecule CDMO in India**, providing end-to-end services for **Key Starting Materials (KSMs), Regulatory Starting Materials (RSMs)**, intermediates, and GMP APIs for **New Chemical Entities (NCEs)** from **Phase I to commercial launch**. #### **Key Strengths:** - **60+ active CDMO projects** across **21 global customers**, including 39 in **commercial** and 21 in **development**. - Focus on **late-stage molecules (Phase II/III)** with high commercialization potential. - Offers **IPR support, robust CMC documentation**, and non-infringing process development to enable faster market entry. - Expertise in **process development (DoE, QbD)**, scale-up, validation, and lifecycle management. #### **R&D & Innovation:** - Operates **three state-of-the-art R&D centers** in Nerul (Maharashtra), Dombivali, and Vapi (Gujarat). - Team of **110 scientists (17 PhDs, 93 MScs)**; FY24–25 R&D spend: ₹42 crores (5% of API, Intermediates & CDMO sales). - In FY25, developed **40+ products at kilo-lab scale**, launched **25+ at plant scale**, and commercialized **55 APIs**. - Holds **58 filed patents (28 granted)**, with 11 new APIs and 14 new intermediates in pipeline. #### **Expansion & Capability Enhancement:** - Launched a **new semi-commercial manufacturing block** at its USFDA-approved Vapi site, enabling **gram-to-ton scale production** for clinical and niche products. - Building capabilities in **peptides, oligonucleotides**, and **Antibody-Drug Conjugate (ADC) linkers**, with commercial operations expected in 2–3 years. --- ### **Manufacturing & Infrastructure** - **Total Multipurpose Reactor Capacity**: Over **1,100 KL**, increasing to **~1,500 KL** with the Atali launch. - **14 dedicated finished API lines**, 6 manufacturing units (3 USFDA-approved). - **Sulphur-Based Chemicals**: In-house production of key inputs like dimethyl sulfate, sodium vinyl sulfonate, and dimethyl urea, supporting Xanthine and pharmaceutical synthesis. --- ### **Capacity Expansion – Key Projects** | **Project** | **Location** | **Capex (₹ Crores)** | **Capacity** | **Timeline** | |-----------|------------|----------------|------------|------------| | **Atali Greenfield CDMO & Intermediates Plant** | Atali, Gujarat (80 acres) | ₹400–425 | ~450 KL (Phase 1); scalable 8–10X | Inaugurated Sept 2025; full ramp-up by Q4 FY26; meaningful revenue from FY27 | | **Xanthine Derivatives Expansion** | Tarapur, Maharashtra | ₹150 | 5,000 → 9,000 MTPA | Phased commissioning from H2 FY25–26; full capacity by Q1 FY27 | - Atali facility is APL’s **7th manufacturing unit**, expected to serve as a **growth engine for CDMO and backward integration in intermediates**. - New reactor capacity enables **multi-site flexible production**, reducing supply chain risk. --- ### **Financial & Operational Metrics (as of FY24–25 / Aug–Nov 2025)** - **Consolidated Revenue (FY24–25 Est.):** ₹2,115 crores (14.3% YoY growth) - **EBITDA (FY24–25):** ₹386 crores - **PAT:** ₹217 crores - **R&D Expenditure:** ₹42 crores (5% of relevant segment sales) - **Employee Base:** ~2,100+ across operations, R&D, quality, and compliance --- ### **Sustainability & ESG Initiatives** - **Green Power**: Solar plant commissioned in Q2 FY25; expected to meet **>33% of total power needs**. - **Bio-briquette boilers** and **Zero Liquid Discharge (ZLD)** plants in operation. - Future plans: Two renewable energy plants to meet **50% of energy demand**. --- ### **Subsidiaries & International Presence** - **Aarti USA Inc** (subsidiary): Supports U.S. sales and distribution. - **Aarti Pharmachem Ltd**: Subsidiary in pharmaceutical manufacturing. - **Ganesh Polychem Limited (JV)**: Commenced operations April 1, 2025. ---